CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV

VANCOUVER, Washington, Aug. 21, 2017, CYDY, (GLOBE NEWSWIRE)  CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that the Company has enrolled 34 patients in its pivotal Phase 2b/3 trial of PRO 140 in combination with antiretroviral therapy (ART) in HIV-infected patients. Thirty-three of the enrolled patients have finished the one-week efficacy endpoint of the study and eleven patients have completed the full 25-week protocol with undetectable viral
http://bit.ly/2vickPY